3 results match your criteria: "University Hospital of Wales and Cardiff University School of Medicine[Affiliation]"

Article Synopsis
  • The REVERXaL study investigates the characteristics and management of hospitalized patients who experience major bleeds related to factor Xa inhibitors (FXai), a new class of anticoagulants.
  • It includes two cohorts: a historical cohort analyzing past patient data and a prospective cohort that evaluates current treatment and patient-reported outcomes over three months.
  • The study aims to provide valuable information on treatment approaches and patient outcomes, potentially improving clinical practices for managing FXai-associated major bleeds.
View Article and Find Full Text PDF

Background: Hip fracture is a leading cause of disability and mortality among older people. During the COVID-19 pandemic, orthopaedic care pathways in the National Health Service in England were restructured to manage pressures on hospital capacity. We examined the indirect consequences of the pandemic for hospital mortality among older patients with hip fracture, admitted from care homes or the community.

View Article and Find Full Text PDF

Erythropoietic protoporphyria (EPP) is an inherited disorder that results from partial deficiency of ferrochelatase (FECH), the terminal enzyme of haem biosynthesis. Current methods that examine the exons and their flanking regions of the FECH gene fail to identify mutations in about one in seven of families with EPP. The presence in some families of intragenic deletions that are not identifiable by current methods for sequencing the FECH gene may partly explain the low sensitivity of mutation detection in EPP.

View Article and Find Full Text PDF